p38alpha and S1P-dependent SREBP2 activation by the SAM-competitive EZH2 inhibitor GSK343 limits its anticancer activity but creates a druggable vulnerability in hepatocellular carcinoma
收藏NIAID Data Ecosystem2026-03-11 收录
官方服务：
资源简介：
This SuperSeries is composed of the SubSeries listed below. Refer to individual Series
创建时间：
2019-11-17
